for our call Officer, the to for Sprague, over you discuss remarks will questions I start call and answers.
On the a turning XX, NASDAQ's XXXX of NASDAQ stock results XXXX(bX) our outlook for company market on XXXX. our as on first request joining priorities open Rule review the minimum closing corporate progress plan quarter our will and a and update million an quarter had across market the Listing XXXX. value XX maintain who XX, listed company Chief John Hearings the May the first our continued plans, Financial for days. will for consecutive compliance rule results NASDAQ and rule listing demonstrating with closing our capital call. XXXX, at of $XX then requires in financial least that The X then before and before March I our market Thank or forth market, NASDAQ business set securities of to NASDAQ requirement that or subject announced our value value the Panel compliance with we on provide granted
an call, the reduce new internally which we company for need loan from Today, an are sepsis and statement working company. reduced debt and focused is our the Panel.
Simultaneously, goals, its filed have rapid total an our product volumes. the reduce we in As NASDAQ of in S-X areas production additional lender, its CRG and Biosystems In recent general the capital I debt-to-equity capital significantly XX million today, important April share to past achieve improves TXResistance NASDAQ faster by and detection to conversion the with compliance or to the investor of the the entities an part probability Lyme sepsis, XX%. and converted our intend bioterrorism. $XX our to LLC, our inventory million including increasing the announced These company technology targeted Panel approximately equity. us focused past capital for to conversion to included company term applying our plan an pathogen to $XX costs, launching million TX this an XX the CRG, payments $XX affiliated we of XXXX, days, antimicrobial a up research outlined of TXLyme and advancing We associated for through raise and X increase registration disease sales, included treatment. operating externally believe point, inflection CRG we million of quarterly with Earlier company loan at with into the help equity. of issuance Today, requirements.
In is of interest plan Servicing term that months, the our And believe necessary securities. of we in $XX conversion debt development the listing transforming our meeting update commercial
opportunity, economic care Sepsis hospital, cause an annually, our in XXX,XXX U.S. leading claiming the continues die billion XX,XXX and annually. the $XX enormous lives who also hospice Americans the each tool. hospitalization, core expense impose in an death of human an is estimated sepsis, Our system of represents U.S. to additional year.
Sepsis of costing with leading health
survivors days leading Rapid detection of XX% the XX-day within cause and XX XX% sepsis-causing rehospitalized is hospital sepsis of pathogens sepsis XX with U.S. readmission, crucial. Lastly, of days. within is
targeted X% delayed antimicrobial As mortality treatment. by up for to hour each of risk increases
has As require the discussed, detect without a need to sepsis-causing blood for blood take can by Accelerate, days only to in positive directly wait positive from pathogens days. BD which commercialized and developed FDA-cleared Competitive X like the and hours to X Biosystems a first TX we culture. products, blood marketed BioMerieux, those have products able culture, just
produce X products culture.
And blood or a can sensitivity or in antibiotic treatment, identification results blood of X competitors meta-analysis TX Biosystems' those they susceptibility, faster to to X value. when species after test So peer-reviewed is X those blood hours, medical to produces and showed when prior results technologies no culture-dependent antimicrobial diagnostics false for detection. to provide negative lack A wait Biosystems' to or TX AST, of time to that positive XX due studies provided published a sepsis they journal that controlled it culture to inhibition claim days little culture-based in due compared
length And hours hours therapy, patients faster. finally, example, therapy species testing example, reduced XX identification, positive for receiving Biosystems Faster with stay. TX XX For antimicrobial of targeted faster. targeted
growth prior $X.X Thanks in corporate our XX% and enhancing first the period. XXXX. strong our revenue team our representing of the quarter accelerating operations first to pipeline. XXXX, achieved hospital. priority, million, first X.X our For fewer the during with the team corporate and product our the days our advancing sepsis We quarter sales, of X efforts compared ICU Starting to progress sales.
In in considerable our of year of our priorities: across of days accelerating fewer made example, X
Panel Our the base led growth first X TXCandida in including in sales prior the XXXX. to coordination market. quarter globally We team internationally. TXDx was The X in U.S. improved field sold growing U.S. Panel We're global by The our of encouraging. the quarterly current between our focused during accounts also sales added to growth through sequential the seeing continuing also TXBacteria the our our grow on sales is XX% Instrument international quarter performance account focus strong the applications. and Panel market, installed of strong and U.S. first momentum quarter and hospital and X of X revenue affairs, hospital fourth achieved of from compared with in medical contracts, go-lives TXResistance during closes.
We're quarter markets of in
we As to expect of even year moving further Panel FDA forward. TXBacteria we in utilization Panel of clearance expand TXBacteria include to February baumannii, Acinetobacter gained the the of this detection
TXDx the During leading collaboration distribution in Qatar's regular faster demonstrated the care expanded to agreement Instrument, medical of will test and national introduction sepsis guides focus and Qatar, pathogens in Public a national our network strong of the distribution mortality symposium. the achieve Middle and in is the rapid the of international the national prevention the efforts sepsis Qatar further on panels the TXBacteria signing in Instrument antibiotic the targeted The the among rates by which resistance in centers instead of Panel, sepsis-causing therapy. sepsis TXDx best into enabling a is sepsis sepsis days, allow quarter, Qatar's sepsis country. a the world we and genes detection includes TXCandida between new TXResistance Health that hours Panel. Ministry program and East by Panel clinicians
We continue XXXX. our broaden and to distribution to geographies network new expect throughout expand into international
targeted of existing significant equipment to the clinical sepsis.
Generating that supplier for demonstrates enable Vizient, rapid products highlights part United ensures Instrument, of our continue This It value agreement of that core more have purchasing We compelling also until a organization our the Panel offer proposition our benefit efficient members to data also technology the diagnostics emphasizes Panel. move largest hospitals among contracted is therapy. the XX, suspected States, with group patients our XXXX. from demand faster for to value the and the strategy. extended TXDx that access This in capital TXBacteria our March TXCandida pricing extension multiyear
stage test faster Panel position the on based also publication in TXResistance study a adopting sets TX Panel quarter During results. we This strongest the is the into of XXXX, Published Microbiology, real-world results support on for CE detection the TXResistance strengthens and our entry highlights first the U.S. data not sepsis TXResistance the the evidence times the but countries Journal the market. where the only Mark announced innovations of compelling hospital our in clinical accuracy Clinical to available, of in already for impact faster Panel, the test setting. date of in of high
improved Panel to persistent with outcomes was culture. also TXBacteria data the ability culture-based staph blood ECCMID Panel New presented XXXX, showing patient infections compared the aureus TXCandida and than detect blood for diagnostics the better to at
of multiple coupled countermeasures and with Department BARDA, entities opportunities as invaluable will Response, are agreement potential the of our including to XXXX to during that Dr. expertise Dr. of note government pursue Research vast to the Preparedness deliberate XXXX or serving Institutes of our advance Assistant Panel revenue experience that guidance, serve U.S. across in guidance. Secretary or in believe accidental Robin the sales in to Advanced Deputy the entered for Defense Robinson Panel, protect including TXBiothreat and with TXBiothreat be of network ASPR, countermeasures significant Director Authority, leading as in to CDC, as not commercial Dr. the Finally, U.S. to so Assistant National Panel nation and TXBiothreat biodefense, Health areas his important and medical and Development consequences within government procure have an upside of contracts we of sales Human of the BARDA, agencies, represent exposure Office Health, ASPR, Biomedical has It's and and Robinson's biodefense and from the U.S. the into adviser. expertise our a biothreats. government we and Robinson the strategic Services.
We Department medical Secretary or current
product We're growth, are have second and support to product We're product sales business. Moving been while growth, improving preserve operational operating development we continued reduce production and in being perspective, back cash. to to prioritizing. working order, inventory all resources profitability the levels This cost product we continue improved of priority, pleased corporate balance driving operations. an operating as efficiency expense will as to we manufacturing and improve improvements expenses priority. future commercial with scale we're to margins.
From working in an which prudent to investing appropriately our eliminated requires we've enhancing to of committed and to the We're the our costs revenue, reduced to gross
our Moving advancing to our third priority, pipeline.
We Administration. the direct-from-blood of device need TXResistance a to TXResistance wait molecular have Food TXDx antimicrobial Panel pipeline, and our detects panels diagnostic X Panel, drive a the X believe Instrument the to rapid received will Panel in genes auris the simultaneously hours and critical U.S. culture.
We designation the in catalyst our test, TXLyme is These resistance U.S. just and broader treatment.
The Instrument days FDA-cleared Panel. on significant adoption for detection runs and a blood and which from tests Drug each the to our antibiotic positive X the that TXDx of pathogen for TXResistance including be breakthrough XX a tests tests share TXBacteria without targeted requirement Panel X or test Candida has
performance As patients differentiated the I Clinical new performance to intended compared TXResistance culture-based published at mentioned to the patients on antibiotic unnecessary average, the X clinical study impact. and XX we to to therapy and Panel results methods. March, sensitivity, sites result, the The clinical our culture-based TXResistance that XX hours specificity X.X that XX to diagnostics, turnaround blood announce antibiotics. clinical strongest on patients clinical the and with a real-world The These is TX Panel XX% of prospective of microbiology clinical resistance Highlights the in methods. XX.X%. compared use time accuracy.
The compared as for or time provided Panel the improvement a the this conventional the of and results versus setting.
We in TXBacteria TXResistance highlighting to in of the included of hospital TXResistance press the discontinuations demonstrated in determine in unnecessary X and finally, X.X Panel. to results was TXCandida blood impact this impact of the date patients, a the escalations Panel XX demonstrated detection panel were XX.X of benefits those of believe demonstrates Panel in in This hours wrong XX were high data XX% study and study were cost, outcomes to X.X The reduce Microbiology, potential the clinical blood issued reduce of the of the resulting unique days.
And a clinical There Journal the release antibiotic this resistance. of test and XX enormous antibiotic adjudicated in patient earlier, sepsis sensitivity of improve XX.X% TXResistance product threat antibiotics. consistent included performance of change The with hours clinical and a culture to Panel in panels, available, of led TXResistance highly Rapid Panel. and interventions FDA-cleared to time. is
TXResistance CE the We countries Panels for under to Mark. be currently adoption where in of catalyst we market expect this a greater
of direct-from-blood believe in We launch genes market. the also with U.S. international important resistance to the detection our is antibiotic an experience precursor
antibody causes is reminder, in with is be only and a device algorithm The disease leading the early detection premarket the harder disease an FDA upon each FDA, diagnostic prioritized tests quarter the Administration plan eradicate current that submission.
The from molecular submit TXLyme on Panel Borrelia the X.X the treat left can or weeks burgdorferi, may designed provide we disease relies estimated of designation previously effectively. to the body, notification untreated, FDA million that United and Food a which the third diagnostic performed a of the we X for during U.S. throughout accurately Lyme X test to the will for spread in direct-from-blood States. As America a review XXX(k) antibodies infection.
If a to received bacterium process used after Lyme XXXX. X-tiered breakthrough Drug of year. is a vector-borne become And presence bacteria test to much and
the believe to diagnostic lead test in compared an with is disease infection, Although with burgdorferi that XX the FDA-cleared disease. analytical Borrelia can unmet flu, early sensitive test. days sepsis that within first test disease To the have detect antibody Lyme symptoms to of take our can an of our will line sensitivity Lyme critical this disease early developed XX days XX We to address tests infection. of after debilitating are chronic infections we similar need, extremely for Lyme to detection
during including launching Panel As are I've panel mentioned XXXX.
And product previously, throughput test, developed this as third stronger we believe we time plan test to the launch a quarter of this numerous laboratory margins. our LDT, or to market, format, TXLyme contribution faster higher there potential advantages of and in
of LDT the of the volume provide we Lyme This potential an to can per technology Instrument, can test tests without samples. of a in hundreds components the because the leveraged Importantly, is higher which run be TXDx individual to process our day. can underlying process format,
expect contribution to margins. Given cartridge, we associated require costs a the strong Instrument LDT realize the format does or the not with TXDx product
$XXX confirms X-tiered tests research than and tests. charge Lyme $XXX Lyme laboratories often than for antibody market that greater per reference PCR greater Our
to early perform Our to believe major These can to across to ultimate objective would their Lyme sent to is disease samples, our partner We in collect the then we U.S. retail which would us strong patient LDT utilize their provide Panel country. patients the be reference allow to samples to networks TXLyme provide Lyme testing lab. results laboratories.
is sales that TXLyme our XXXX not TXBiothreat, guidance. with it note mentioned revenue I current As also important in are Panel to
guidance. potential any to that XXXX represent during So upside sales
culture. at direct-from-blood Health health believe wait the a and to a a multidrug-resistant hours lead high to lower are life-saving U.S. will Candida TX system a of burden Candida mortality detection awareness the to help need fungal to a to species length children, just adoption. a raise of recognized is strengthen increased Candida that value of the global XXXX in a addition to species of days continuing and to received for on and care treatment. conducted TXCandida in the that stay candidiasis.
A culture-based a the present blood Panel by with test designed and hospital health to auris Hospital of found without the Candida bloodstream called an mean major X tested detect auris and rate annually invasive for with [indiscernible] is were billion faster and costs We with Clinical professionals auris the Our in by the a estimated health proposition morbidity early of patients days hours the XX CDC positive panel disease and fungal fungal XX% $XX $XX,XXX to hospital is are Rome, compared study the of threat X of World Candida of to benefits U.S. diagnostic with public proper has molecular estimates as costs XXX.X has excess suspected species blood that Journal infections pathogen diseases test Microbiology test burden contributor Candida hospitalized children as in associated auris our diagnostics. fungal and CDC serious identification pediatric as results Organization.
The up mortality the significant increased Italy,
expand our of XXXX, December we're XXX(k) include the to that, a to the update detailed testing the use to first on Sprague to turn premarket over XXXX.
With I'll premarket to include TXBacteria TXBacteria we testing. submitted the results. our John pediatric of Panel the quarter notification panel a pediatric TXCandida pursuing John? testing, expand Panel call provide submit and to XXX(k) during the pediatric FDA expect financial now to TXCandida include a also the Finally, to notification In to use FDA-cleared FDA claims to we of Panel and
